Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report

Jun.08
Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
A smoke-free nicotine policy report argues that tobacco harm reduction should move beyond product bans and health warnings into tax policy, insurance pricing and risk-based regulation. While some projections remain open to debate, the report highlights a wider challenge: nicotine products, technologies and consumer behavior have changed sharply over the past decade, and regulatory systems may need new tools to better align tobacco control with harm-reduction goals.

Key Points

  • New Policy Lens: The report shifts the harm-reduction debate from product regulation alone to tax policy, insurance pricing and financial incentives.
  • Tax as Switching Tool: Its key tax argument is not simply lower taxes for lower-risk products, but using price signals to encourage adult smokers to move away from combustion.
  • Insurance as Incentive: The report raises whether insurers may one day price policies differently based on the type of nicotine product an applicant uses.
  • Evidence and Verification: Biomarkers could give regulators and insurers a more objective way to distinguish smoking from other nicotine-use patterns.
  • Regulatory Adaptation: As nicotine products and consumer behavior change, tobacco control may need new frameworks rather than applying old rules to a changed market.

2Firsts

June 8, 2026

A policy report on smoke-free nicotine argues that global regulation should move beyond product bans, health warnings and market authorization to include risk-based taxation, insurance underwriting and financial incentives.

The report, titled Nicotine 2030: An Outlook on Smoke-Free Nicotine, Global Health, and Regulatory Innovation (the “Report”), is intended for public-health and regulatory-policy stakeholders. It was compiled by Derek Yach of Global Health Strategies LLC. Yach is a public-health expert who has long been involved in global tobacco-control issues and previously contributed to the development of the WHO Framework Convention on Tobacco Control (FCTC). The Report was supported by Zanoprima Lifesciences, a U.K.-based life-sciences company focused on the development of high-purity, tobacco-free synthetic nicotine products and related production processes.

Some of the report’s long-term projections and policy conclusions may remain open to debate and require further verification. Even so, some of the ideas and perspectives it raises may offer new insights for global tobacco control and tobacco harm-reduction discussions.

 

Bringing Tax and Insurance Into Nicotine Regulation: Insights From a Tobacco Harm-Reduction Report
Cover page of Nicotine 2030, a report by Derek Yach on smoke-free nicotine, global health and regulatory innovation.| Source: Derek Yach LinkedIn.

Tax as a Switching Tool, Not Only a Tobacco-Control Tool

One of the report’s more notable points is that it moves tobacco harm reduction from the public-health arena into fiscal policy. Citing analysis from the International Monetary Fund (IMF), the report says nicotine excise taxes should reflect differences in product risk, rather than treating all nicotine products as equivalent.

Under the framework discussed in the report, combustible cigarettes would remain at the top of the tax scale, while heated tobacco products, vaping liquids, oral nicotine pouches and nicotine-replacement therapies (NRT) would carry lower tax burdens based on relative risk.

The point is not only that lower-risk products should be taxed less. It is that taxation can serve as a price signal for smokers to switch. Traditional tobacco-control taxation mainly seeks to reduce consumption by raising cigarette prices. The report argues that when lower-risk alternatives exist, fiscal policy should not weaken the economic incentive for adult smokers to move away from combustion.

This discussion also echoes a view previously published by 2Firsts. Indian nicotine-policy expert Samrat Chowdhery argued in a contributed article that Tobacco Price Elasticity (TPE) is often oversimplified. Without viable alternatives and cessation support, high tobacco taxes may place a heavier burden on vulnerable smokers and stimulate illicit markets, without delivering proportional public-health gains.

The report does not treat taxation as a stand-alone solution. In India, it says lifting the e-cigarette ban is a key condition in the relevant policy scenario. In Indonesia, where cigarette taxes are already high, the report says further gains would come mainly from improving access to tobacco harm-reduction products, rather than simply raising cigarette taxes further.

The section therefore raises a sharper question: if the policy goal is to reduce the harm caused by combustible tobacco, should taxation focus only on making cigarettes more expensive, or should it also use risk tiers and price differences to create clearer economic incentives for adult smokers to switch to lower-risk products?

Should Different Tobacco and Nicotine Users Face Different Insurance Pricing?

Another point raised by the report is that the insurance industry may become a new factor in tobacco harm-reduction policy. Citing work by Swiss Re on smoker risk classification, the report says life insurers may eventually need to move beyond treating all nicotine users as “smokers.”

The issue matters because it affects premiums. If cigarette smokers, former smokers and users of non-combustible nicotine products face different health risks, insurers may consider more detailed categories when assessing applicants and setting prices.

The report says biomarker research could provide part of the technical basis for that shift. It cites recent studies using untargeted omics methods, which found that a small set of biomarkers can reliably distinguish between cigarette smokers, heated tobacco users, e-cigarette users, oral nicotine-product users and nicotine-replacement therapy (NRT) users.

If such testing methods become standardized and accepted by regulators and insurers, companies may have stronger grounds to classify nicotine users by different levels of risk. The report estimates that global adoption of risk-based life-insurance underwriting could lead to about US$71 billion in annual premium adjustments. That remains a modelled estimate, dependent on testing, industry adoption and regulatory acceptance.

The broader implication is that tobacco harm reduction may no longer be only about whether products can be sold. It may also enter insurance pricing and health-risk assessment. Whether insurers will price policies differently based on the type of nicotine product an applicant uses — and whether those price differences could influence consumers’ choices or switching between nicotine products — deserves further attention.

The Risk of Marking a Moving Boat

When markets, products and consumer behavior have changed, static regulatory ideas, frameworks and methods may drift away from the original goals of tobacco control and tobacco harm reduction.

The Chinese idiom ke zhou qiu jian captures that risk: carving a mark on a moving boat to find a sword dropped in the water. For nicotine regulation, product formats, technology pathways and consumer behavior have changed profoundly over the past decade. Regulation, taxation and public-health management should evolve accordingly, with a more open mindset and more creative thinking, adopting new policies, methods and technologies to better achieve the goals of tobacco control and harm reduction.

2Firsts welcomes more submissions from experts and researchers. Please contact: alan@2firsts.com

Cover image generated by AI.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Germany Seizes 56 Pallets of Illegal Vapes, Probe Estimates €1.8 Million Tax Loss
Germany Seizes 56 Pallets of Illegal Vapes, Probe Estimates €1.8 Million Tax Loss
German authorities have seized dozens of pallets of illegal disposable vapes in a criminal investigation, with the products estimated to have caused at least €1.8 million in tax losses. The case has also raised concerns over cross-border supply chains linked to unauthorized nicotine products entering the European market.
Jul.14
South Korean Lawmaker Jeong Jin-wook Pushes Synthetic Nicotine Vape Probe, Highlighting Supply Chain and Tax Concerns
South Korean Lawmaker Jeong Jin-wook Pushes Synthetic Nicotine Vape Probe, Highlighting Supply Chain and Tax Concerns
South Korean lawmaker Jeong Jin-wook has again called for stronger government action against liquid synthetic nicotine vape manufacturers and sellers, alleging that some businesses may have avoided regulation through product labeling changes and corporate restructuring. According to Newsworks, JNILBO and other Korean reports, Jeong has held his third press conference on the issue, calling for a government-wide investigation. The dispute involves whether synthetic nicotine products should fall under tobacco regulations, tax implications and supply-chain transparency. South Korean government agencies have previously said some estimates of potential tax losses cannot be verified due to limited sales data.
Jul.27
Major U.S.  Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
Major U.S. Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
New York vape distributor Ecto World, which operates as Demand Vape, hired political consultant Roger Stone to lobby the Executive Office of the President on regulation of vaping and related products while facing state enforcement and multiple lawsuits. Public lobbying disclosures show that Ecto World paid at least $300,000 for the work through June 30, 2026. Separately, New York State announced in March that more than 28,500 pounds of vaping products tied to the company had been seized, while New York City and the state have pursued legal or enforcement actions. Public records do not show that the lobbying directly changed any specific regulatory or enforcement outcome.
Sep.08
FTC Scrutinizes Fifty Bar’s “Made in America” Claims as Vape Marketing Faces New Compliance Risk
FTC Scrutinizes Fifty Bar’s “Made in America” Claims as Vape Marketing Faces New Compliance Risk
The Federal Trade Commission sent a warning letter to Lucky Bar Holdings LLC over “Made in the USA” claims tied to Fifty Bar vape products, saying staff had reason to believe the products may be imported in whole or in significant part despite unqualified U.S.-origin marketing claims.
Jul.20
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28